Alexion Pharma (ALXN) Tops Q4 EPS by 1c; Guides Below the Street, $1B Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Alexion Reports Fourth Quarter and Full Year 2016 Results and Provides Financial Guidance for 2017
February 16, 2017 6:30 AM ESTTotal Revenues of $3.084 Billion, an 18% Increase Over 2015 and 22% Volume Increase Global Soliris® Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS Strensiq® and Kanuma® Global Launches Progress With New Patients Starting on Treatment Filed Regulatory Submissions for Soliris in Patients with Refractory gMG in the U.S. and Europe ALXN1210 Phase 3 Studies Underway in Patients with PNH and aHUS Alexion Board Increases Authorized Share Repurchase to a Total of $1 Billion... More
